NanoString Technologies (NASDAQ:NSTG) Research Coverage Started at StockNews.com

Investment analysts at StockNews.com began coverage on shares of NanoString Technologies (NASDAQ:NSTG) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

NanoString Technologies Stock Performance

The stock has a market cap of $5.07 million, a PE ratio of -0.03 and a beta of 1.24. NanoString Technologies has a fifty-two week low of $0.05 and a fifty-two week high of $11.78. The business has a fifty day moving average of $0.36 and a 200 day moving average of $1.11.

Hedge Funds Weigh In On NanoString Technologies

A number of institutional investors and hedge funds have recently bought and sold shares of NSTG. Advisor Group Holdings Inc. boosted its holdings in NanoString Technologies by 21.1% in the 1st quarter. Advisor Group Holdings Inc. now owns 4,595 shares of the biotechnology company’s stock worth $162,000 after acquiring an additional 800 shares during the period. JPMorgan Chase & Co. boosted its holdings in NanoString Technologies by 38.1% in the 1st quarter. JPMorgan Chase & Co. now owns 86,603 shares of the biotechnology company’s stock worth $3,009,000 after acquiring an additional 23,872 shares during the period. AlphaCrest Capital Management LLC purchased a new position in NanoString Technologies in the 1st quarter worth approximately $267,000. MetLife Investment Management LLC boosted its holdings in NanoString Technologies by 57.4% in the 1st quarter. MetLife Investment Management LLC now owns 24,478 shares of the biotechnology company’s stock worth $851,000 after acquiring an additional 8,930 shares during the period. Finally, Lord Abbett & CO. LLC boosted its holdings in NanoString Technologies by 1.9% in the 1st quarter. Lord Abbett & CO. LLC now owns 139,659 shares of the biotechnology company’s stock worth $4,853,000 after acquiring an additional 2,542 shares during the period.

NanoString Technologies Company Profile

NanoString Technologies, Inc develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system.